Tarsus Pharmaceuticals, Inc. (TARS) bonds
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$72.76M
Long-term debt
Net debt
-$131.83M
After $204.60M of cash
Implied interest rate
12.39%
FY2025 interest ÷ average debt
Interest coverage
-7.9×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in Tarsus Pharmaceuticals's 10-Q for the period ended Apr 30, 2024
Tarsus Pharmaceuticals's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Pharmakon Credit Facility, Tranche One | $25.00M |
| Pharmakon Credit Facility, Tranche Three | $50.00M |
| Pharmakon Credit Facility, Tranche Two | $50.00M |
See a number that looks wrong?